Clinical trial
Bortezomib in Treating Patients With Metastatic Kidney Cancer
NCT00276614 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00276614 |
|---|---|
| Title | Bortezomib in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 4 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jan 13, 2006 |
| Last update posted | Sep 1, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: